Viqueira FAM, Ramírez NSJ, Miyares DE

Language: Spanish
References: 9
Page:
PDF size: 48.77 Kb.

ABSTRACT

Psoriasis is a chronic inflammatory skin disease with clinical variation and evolution. The etiology of psoriasis is unknown although its origin is considered multifactorial like ambient, immunological and genetics. Infections, medications and stress are considered the most important ambient factors. Psoriasis is a serious illness and is very important avoid the tendency to sub estimate it. Changes in hepatic structures including hepatomegaly are described in psoriatic patients but it is controversial if these changes respond only to psoriasis or also due to the intervention of others factors like previous treatments or others. In this article are described three patients with previous diagnosis of Hepatitis C and further apparition of cutaneous psoriatic lesions.

REFERENCES

1. Robin A.C, Graham-Brown, ImrichSarkany. The hepatobiliary system and the skin. Chapter 164 . DIGM Fitzpatrick´s. (2000). Dermatology in General Medicine. CD ROM, Enigma Electronic Publication, Fifth Edition.

2. Yamamoto T, Katayama I, Nishioka K. Oral psoriasis in a patient with hepatitis C.European Journal of Dermatology. Volume 12, Number 1, 75-6, January - February 2002, Cas cliniques. [Internet]:[Citado 2 Dic 2010]; [Aprox.2p.].Disponible en: http://www.john-libbeyeurotext.fr/en/revues/ medecine/ejd/e-docs/00/01/88/FC/article.phtml 3.

3. Cohen AD, Weitzman D, Birkenfeld S, Dreiher J Psoriasis Associated with Hepatitis C but Not with Hepatitis B. Dermatology Vol. 220, No. 3, 2010[Internet];[Citado 2 Dic 2010];[Aprox. 3 p.]. Disponible en:http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowAbstract&ArtikelNr=286131&Ausgabe=254038&ProduktNr=224164

4. Taglione E, Vatteroni ML, Martini P y col. Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. J Rheumatol. 1999 Feb; 26(2):370-2.[Internet]:[Citado 14 Nov 2010];[Aprox.2p.]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/9972971

5. Sánchez Carazo JL. Seguridad del Etanercept en la psoriasis.Drug Safety, 29(8):675-685, 2006. [Internet]:[Citado 14 Nov 2010];[Aprox.2p.]. Disponible en: http://www.siicsalud.com/dato/crosiic.php/86099

6. Cecchi R MD, Bartoli L MD. Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept) Dermatology Online Journal, 2006. Volume 12 Number7:4. [Internet]:[Citado 14 Nov 2010];[Aprox.2p.]. Disponible en: http://webcache.googleusercontent.com/search?q=cache:t8YXyPVqj1Y J:dermatology.cdlib.org/127/reviews/psoriasis/cecchi.html+hepatitis+c+%2B psoriasis&cd=1&hl=es&ct=clnk&gl=cu

7. Piper L.Psoriasis linked to hepatitis C. Dermatology 2010;220: 218-222. [Internet]:[Citado 14 Nov 2010];[Aprox.2p.].Disponible en: http://www. medwire-news.md/60/87526/Psoriasis/Psoriasis_linked_to_hepatitis_C.html

8. Frankel AJ, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF Jr, Gottlieb AB; Tratamiento de la psoriasis en pacientes con hepatitis C: del Cuerpo Médico de la National Psoriasis Foundation. J Am AcadDermatol. 2009,61(6):1044-55. [Internet];[Citado 2 Dic 2010];[Aprox. 3 p.]. Disponible en:http://webcache.googleusercontent.com/search?q=cache:t8YXyPVqj1YJ:dermatology.cdlib.org/127/reviews/psoriasis /cecchi.html+hepatitis+c+%2B psoriasis&cd=1&hl=es&ct=clnk&gl=cu

9. Goldman, E. Options limited for comorbid psoriasis, hepatitis C. (Psoriasis) Skin & Allergy News .October 1, 2007[Internet];[Citado 2 Dic 2010];[Aprox. 2 p.]. Disponible en: http://www.highbeam.com/doc/1G1-170017598.html#mlt.